

Item S2. Supplementary Tables

Table a. Attributes of interventional clinical trials from ClinicalTrials.gov: October 1, 2007, through September 27, 2010

Trial attribute	CKD N=308	ESRD/CKD on dialysis N=299	Renal transplant N=194	Glomerular disease N=86	Neoplastic N=12	AKI N=84	Metabolic/el ectrolyte disorders N=3	Nehprolithia sis N=14	Pyelonephri tis N=7	Care delivery models N=5	Other <sup>a</sup> N=56
Primary purpose	n=289	n=282	n=188	n=85	n=11	n=79	n=3	n=14	n=7	n=4	n=54
Treatment	231 (79.9)	218 (77.3)	140 (74.5)	81 (95.3)	9 (81.8)	35 (44.3)	1 (33.3)	12 (85.7)	7 (100.0)	0 (0.0)	29 (53.7)
Prevention	29 (10.0)	32 (11.3)	36 (19.1)	3 (3.5)	1 (9.1)	39 (49.4)	1 (33.3)	0 (0.0)	0 (0.0)	1 (25.0)	18 (33.3)
Diagnostic	5 (1.7)	5 (1.8)	5 (2.7)	0 (0.0)	0 (0.0)	4 (5.1)	1 (33.3)	1 (7.1)	0 (0.0)	1 (25.0)	1 (1.9)
Supportive care	5 (1.7)	11 (3.9)	3 (1.6)	1 (1.2)	1 (9.1)	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	1 (1.9)
Screening	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.7)
Health services research	5 (1.7)	6 (2.1)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)	0 (0.0)
Basic science	13 (4.5)	10 (3.5)	3 (1.6)	0 (0.0)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (5.6)
Phase	n=308	n=299	n=194	n=86	n=12	n=84	n=3	n=14	n=7	n=5	n=56
0	0 (0.0)	1 (0.3)	1 (0.5)	0 (0.0)	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
II	46 (14.9)	15 (5.0)	9 (4.6)	9 (10.5)	1 (8.3)	2 (2.4)	0 (0.0)	0 (0.0)	1 (14.3)	1 (20.0)	15 (26.8)
I/II	7 (2.3)	9 (3.0)	15 (7.7)	4 (4.7)	0 (0.0)	1 (1.2)	1 (33.3)	1 (7.1)	0 (0.0)	0 (0.0)	1 (1.8)
II	48 (15.6)	56 (18.7)	25 (12.9)	18 (20.9)	5 (41.7)	6 (7.1)	1 (33.3)	2 (14.3)	2 (28.6)	0 (0.0)	12 (21.4)
II/III	13 (4.2)	9 (3.0)	7 (3.6)	4 (4.7)	0 (0.0)	9 (10.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.6)
III	55 (17.9)	54 (18.1)	22 (11.3)	19 (22.1)	1 (8.3)	15 (17.9)	0 (0.0)	2 (14.3)	2 (28.6)	1 (20.0)	6 (10.7)
IV	66 (21.4)	64 (21.4)	71 (36.6)	17 (19.8)	0 (0.0)	29 (34.5)	0 (0.0)	1 (7.1)	1 (14.3)	0 (0.0)	9 (16.1)
N/A	73 (23.7)	91 (30.4)	44 (22.7)	15 (17.4)	5 (41.7)	21 (25.0)	1 (33.3)	8 (57.1)	1 (14.3)	3 (60.0)	11 (19.6)
Allocation	n=303	n=292	n=189	n=86	n=11	n=84	n=3	n=14	n=7	n=5	n=55
Randomized	216 (71.3)	207 (70.9)	138 (73.0)	44 (51.2)	6 (54.5)	76 (90.5)	2 (66.7)	11 (78.6)	6 (85.7)	4 (80.0)	47 (85.5)
Non-randomized	87 (28.7)	85 (29.1)	51 (27.0)	42 (48.8)	5 (45.5)	8 (9.5)	1 (33.3)	3 (21.4)	1 (14.3)	1 (20.0)	8 (14.5)
Intervention model	n=307	n=296	n=194	n=86	n=10	n=83	n=3	n=14	n=7	n=5	n=55
Single group	72 (23.5)	74 (25.0)	49 (25.3)	42 (48.8)	4 (40.0)	9 (10.8)	1 (33.3)	2 (14.3)	1 (14.3)	2 (40.0)	7 (12.7)
Parallel	201 (65.5)	174 (58.8)	131 (67.5)	40 (46.5)	6 (60.0)	65 (78.3)	1 (33.3)	11 (78.6)	6 (85.7)	3 (60.0)	41 (74.5)
Crossover	31 (10.1)	44 (14.9)	6 (3.1)	3 (3.5)	0 (0.0)	7 (8.4)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	7 (12.7)
Factorial	3 (1.0)	4 (1.4)	8 (4.1)	1 (1.2)	0 (0.0)	2 (2.4)	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)
Masking	n=307	n=296	n=194	n=86	n=10	n=84	n=3	n=14	n=7	n=5	n=56
Open	175 (57.0)	209 (70.6)	160 (82.5)	73 (84.9)	8 (80.0)	42 (50.0)	2 (66.7)	5 (35.7)	2 (28.6)	4 (80.0)	23 (41.1)
Single blind	28 (9.1)	23 (7.8)	6 (3.1)	2 (2.3)	0 (0.0)	11 (13.1)	0 (0.0)	3 (21.4)	1 (14.3)	1 (20.0)	6 (10.7)
Double blind	104 (33.9)	64 (21.6)	28 (14.4)	11 (12.8)	2 (20.0)	31 (36.9)	1 (33.3)	6 (42.9)	4 (57.1)	0 (0.0)	27 (48.2)

Values are n (%). Columns are not mutually exclusive; a study may be counted in more than one column.

<sup>a</sup>Other includes drug studies, pharmacokinetic studies, and studies with other interventions with renal endpoints. Abbreviations: AKI, acute kidney infection; CKD, chronic kidney disease; ESRD, end-stage renal disease.

Table b. Enrollment and endpoint classification

Trial attribute	CKD N=308	ESRD/CKD on dialysis N=299	Renal transplant N=194	Glomerular disease N=86	Neoplastic N=12	AKI N=84	Metabolic/el ectrolyte disorders N=3	Nehprolithia sis N=14	Pyelonephri tis N=7	Care delivery models N=5	Other <sup>a</sup> N=56
Enrollment	n=304	n=293	n=194	n=85	n=12	n=83	n=3	n=14	n=7	n=5	n=55
Mean (SD)	257 (1070)	131 (225)	122 (154)	82 (118)	71 (72)	280 (448)	55 (48)	117 (84)	152 (104)	209 (171)	193 (476)
Median (IQR)	69 (32-161)	62 (26-144)	69 (30-152)	30 (20-100)	50 (33-85)	150 (45-368)	50 (10-105)	90 (54-200)	140 (50-225)	140 (140-210)	60 (30-126)
Patient enrollment	n=304	n=293	n=194	n=85	n=12	n=83	n=3	n=14	n=7	n=5	n=55
0	2 (0.7)	0 (0.0)	1 (0.5)	0 (0.0)	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
1-10	9 (3.0)	19 (6.5)	13 (6.7)	8 (9.4)	1 (8.3)	3 (3.6)	1 (33.3)	1 (7.1)	1 (14.3)	0 (0.0)	3 (5.5)
11-50	116 (38.2)	107 (36.5)	65 (33.5)	45 (52.9)	6 (50.0)	17 (20.5)	1 (33.3)	2 (14.3)	1 (14.3)	0 (0.0)	23 (41.8)
51-100	70 (23.0)	69 (23.5)	45 (23.2)	11 (12.9)	4 (33.3)	17 (20.5)	0 (0.0)	5 (35.7)	0 (0.0)	1 (20.0)	13 (23.6)
101-500	83 (27.3)	85 (29.0)	64 (33.0)	20 (23.5)	1 (8.3)	34 (41.0)	1 (33.3)	6 (42.9)	5 (71.4)	4 (80.0)	11 (20.0)
501-1000	15 (4.9)	10 (3.4)	5 (2.6)	1 (1.2)	0 (0.0)	8 (9.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (5.5)
>1000	9 (3.0)	3 (1.0)	1 (0.5)	0 (0.0)	0 (0.0)	3 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (3.6)
Study duration (months)	n=280	n=275	n=174	n=82	n=11	n=81	n=3	n=13	n=7	n=4	n=52
Mean (SD)	23 (19)	21 (16)	34 (24)	31 (22)	44 (38)	23 (15)	19 (16)	17 (11)	31 (39)	31 (24)	21 (18)
Median (IQR)	19 (12-31)	17 (9-28)	27 (18-46)	25 (16-37)	37 (13-61)	18 (13-28)	13 (8-37)	19 (5-24)	12 (9-37)	28 (11-51)	16 (9-25)
Endpoint classification	n=267	n=255	n=166	n=78	n=11	n=68	n=2	n=12	n=7	n=4	n=49
Safety	21 (7.9)	10 (3.9)	7 (4.2)	5 (6.4)	0 (0.0)	4 (5.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7 (14.3)
Efficacy	84 (31.5)	83 (32.5)	45 (27.1)	27 (34.6)	4 (36.4)	33 (48.5)	0 (0.0)	8 (66.7)	4 (57.1)	3 (75.0)	14 (28.6)
Safety/efficacy	117 (43.8)	132 (51.8)	102 (61.4)	45 (57.7)	5 (45.5)	26 (38.2)	2 (100.0)	3 (25.0)	3 (42.9)	1 (25.0)	18 (36.7)
Bio-equivalence	1 (0.4)	2 (0.8)	1 (0.6)	0 (0.0)	0 (0.0)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (8.2)
Bio-availability	0 (0.0)	1 (0.4)	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pharmacokinetics	29 (10.9)	20 (7.8)	8 (4.8)	0 (0.0)	2 (18.2)	2 (2.9)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)	1 (2.0)
Pharmacodynamics	7 (2.6)	2 (0.8)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.1)
Pharmacokinetics/dynamics	8 (3.0)	5 (2.0)	0 (0.0)	1 (1.3)	0 (0.0)	2 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (6.1)
Missing, n/N (%)	41/308 (13.3)	44/299 (14.7)	28/194 (14.4)	8/86 (9.3)	1/12 (8.3)	16/84 (19.0)	1/3 (33.3)	2/14 (14.3)	0/7 (0.0)	1/5 (20.0)	7/56 (12.5)
Number of primary outcomes measured	n=304	n=294	n=191	n=86	n=11	n=81	n=3	n=14	n=7	n=5	n=56
Mean (SD)	1.2 (0.69)	1.2 (0.78)	1.2 (0.77)	1.2 (1.11)	1.2 (0.40)	1.2 (0.73)	1.0 (0.00)	1.1 (0.27)	1.0 (0.00)	1.0 (0.00)	1.2 (0.62)
Median (IQR)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)	1 (1.0-1.0)
A primary outcome measures safety, n/N (%)	87/286 (30.4)	89/284 (31.3)	61/181 (33.7)	39/83 (47.0)	2/11 (18.2)	35/81 (43.2)	2/3 (66.7)	2/13 (15.4)	2/7 (28.6)	0/5 (0.0)	20/54 (37.0)
Number of secondary outcomes measured	n=304	n=294	n=192	n=86	n=11	n=81	n=3	n=14	n=7	n=5	n=56
Mean (SD)	2.3 (3.21)	2.2 (2.57)	2.8 (3.66)	1.9 (1.71)	2.0 (2.00)	2.0 (2.26)	0.7 (0.58)	1.4 (1.50)	1.9 (1.95)	1.4 (0.89)	1.8 (2.09)
Median (IQR)	1 (1.0-3.0)	1 (1.0-3.0)	1 (1.0-4.0)	1 (1.0-3.0)	1 (1.0-3.0)	1 (0.0-3.0)	1 (0.0-1.0)	1 (0.0-3.0)	1 (1.0-2.0)	1 (1.0-1.0)	1 (0.5-2.5)
A secondary outcome measures safety, n/N (%)	93/291 (32.0)	94/284 (33.1)	79/185 (42.7)	44/83 (53.0)	2/11 (18.2)	35/81 (43.2)	2/3 (66.7)	1/14 (7.1)	3/7 (42.9)	0/5 (0.0)	14/54 (25.9)

Unless otherwise noted, values are n (%). Columns are not mutually exclusive; a study may be counted in more than one column.

<sup>a</sup>Other includes drug studies, pharmacokinetic studies, and studies with other interventions with renal endpoints.

Abbreviations: AKI, acute kidney infection; CKD, chronic kidney disease; ESRD, end-stage renal disease; IQR, interquartile range; SD, standard deviation.

**Table c. Study arms, interventions, patient eligibility, and monitoring**

Trial attribute	CKD N=308	ESRD/CKD on dialysis N=299	Renal transplant N=194	Glomerular disease N=86	Neoplastic N=12	AKI N=84	Metabolic/el ectrolyte disorders N=3	Nehprolithia sis N=14	Pyelonephri tis N=7	Care delivery models N=5	Other <sup>a</sup> N=56
Number of arms	n=294	n=288	n=190	n=86	n=11	n=83	n=3	n=14	n=7	n=5	n=53
1	70 (23.8)	73 (25.3)	47 (24.7)	43 (50.0)	5 (45.5)	8 (9.6)	1 (33.3)	2 (14.3)	1 (14.3)	2 (40.0)	9 (17.0)
2	152 (51.7)	162 (56.3)	113 (59.5)	36 (41.9)	5 (45.5)	63 (75.9)	1 (33.3)	9 (64.3)	5 (71.4)	3 (60.0)	36 (67.9)
3	39 (13.3)	23 (8.0)	19 (10.0)	5 (5.8)	0 (0.0)	7 (8.4)	0 (0.0)	2 (14.3)	1 (14.3)	0 (0.0)	4 (7.5)
4	21 (7.1)	15 (5.2)	10 (5.3)	2 (2.3)	1 (9.1)	5 (6.0)	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	1 (1.9)
5 or more	12 (4.1)	15 (5.2)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3 (5.7)
Arm types <sup>b</sup>	n=285	n=272	n=172	n=76	n=8	n=79	n=3	n=13	n=7	n=4	n=52
Active comparator	126 (44.2)	143 (52.6)	100 (58.1)	31 (40.8)	6 (75.0)	50 (63.3)	1 (33.3)	7 (53.8)	6 (85.7)	0 (0.0)	22 (42.3)
No-intervention	25 (8.8)	30 (11.0)	22 (12.8)	1 (1.3)	0 (0.0)	6 (7.6)	0 (0.0)	1 (7.7)	0 (0.0)	2 (50.0)	6 (11.5)
Experimental	194 (68.1)	205 (75.4)	122 (70.9)	62 (81.6)	5 (62.5)	49 (62.0)	2 (66.7)	9 (69.2)	4 (57.1)	3 (75.0)	35 (67.3)
Placebo comparator	90 (31.6)	50 (18.4)	20 (11.6)	10 (13.2)	3 (37.5)	24 (30.4)	1 (33.3)	5 (38.5)	2 (28.6)	0 (0.0)	24 (46.2)
Sham comparator	3 (1.1)	1 (0.4)	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other	13 (4.6)	15 (5.5)	11 (6.4)	5 (6.6)	0 (0.0)	3 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	6 (11.5)
Intervention types(b)	n=308	n=299	n=194	n=86	n=12	n=84	n=3	n=14	n=7	n=5	n=56
Drug	242 (78.6)	163 (54.5)	157 (80.9)	82 (95.3)	8 (66.7)	60 (71.4)	3 (100.0)	8 (57.1)	6 (85.7)	0 (0.0)	42 (75.0)
Procedure	14 (4.5)	37 (12.4)	21 (10.8)	2 (2.3)	3 (25.0)	12 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (5.4)
Biologic or vaccine	3 (1.0)	13 (4.3)	13 (6.7)	4 (4.7)	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (7.1)
Behavior	20 (6.5)	13 (4.3)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (40.0)	0 (0.0)
Device	12 (3.9)	42 (14.0)	1 (0.5)	0 (0.0)	3 (25.0)	10 (11.9)	0 (0.0)	5 (35.7)	0 (0.0)	0 (0.0)	3 (5.4)
Radiation	1 (0.3)	0 (0.0)	2 (1.0)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dietary supplement	14 (4.5)	16 (5.4)	3 (1.5)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (14.3)	0 (0.0)	2 (3.6)
Genetic	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other	23 (7.5)	38 (12.7)	8 (4.1)	2 (2.3)	1 (8.3)	6 (7.1)	0 (0.0)	1 (7.1)	1 (14.3)	3 (60.0)	6 (10.7)
Sex of participants	n=308	n=299	n=194	n=86	n=12	n=84	n=3	n=14	n=7	n=5	n=56
Female	3 (1.0)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (28.6)	0 (0.0)	0 (0.0)
Male	2 (0.6)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (8.9)
Both	303 (98.4)	297 (99.3)	194 (100.0)	86 (100.0)	12 (100.0)	83 (98.8)	3 (100.0)	14 (100.0)	5 (71.4)	5 (100.0)	51 (91.1)
Accepts healthy volunteers, n/N (%)	49/304 (16.1)	16/294 (5.4)	10/192 (5.2)	3/86 (3.5)	0/12 (0.0)	5/84 (6.0)	0/3 (0.0)	3/14 (21.4)	0/7 (0.0)	0/5 (0.0)	17/56 (30.4)
Age restrictions <sup>b</sup>	n=308	n=299	n=194	n=86	n=12	n=84	n=3	n=14	n=7	n=5	n=56
Max age of ≤18	5 (1.6)	5 (1.7)	2 (1.0)	6 (7.0)	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)	4 (57.1)	1 (20.0)	3 (5.4)
Min age of ≥65	2 (0.6)	1 (0.3)	2 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Excludes ages >65	33 (10.7)	20 (6.7)	51 (26.3)	33 (38.4)	1 (8.3)	1 (1.2)	2 (66.7)	3 (21.4)	5 (71.4)	1 (20.0)	15 (26.8)
Min age of ≥75	0 (0.0)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Excludes ages >75	105 (34.1)	54 (18.1)	86 (44.3)	48 (55.8)	2 (16.7)	7 (8.3)	2 (66.7)	3 (21.4)	5 (71.4)	1 (20.0)	20 (35.7)
Has DMC	n=308	n=299	n=194	n=86	n=12	n=84	n=3	n=14	n=7	n=5	n=56
No	151 (49.0)	151 (50.5)	84 (43.3)	37 (43.0)	5 (41.7)	44 (52.4)	3 (100.0)	9 (64.3)	3 (42.9)	3 (60.0)	28 (50.0)
Yes	118 (38.3)	113 (37.8)	82 (42.3)	39 (45.3)	5 (41.7)	36 (42.9)	0 (0.0)	4 (28.6)	4 (57.1)	2 (40.0)	23 (41.1)
Unknown	39 (12.7)	35 (11.7)	28 (14.4)	10 (11.6)	2 (16.7)	4 (4.8)	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	5 (8.9)

Unless otherwise noted, values are n (%). Columns are not mutually exclusive; a study may be counted in more than one column. Abbreviations: AKI, acute kidney infection; CKD, chronic kidney disease; DMC, data monitoring committee; ESRD, end-stage renal disease; max, maximum; min, minimum

<sup>a</sup>Other includes drug studies, pharmacokinetic studies, and studies with other interventions with renal endpoints. <sup>b</sup>Rows are not mutually exclusive.

**Table d. Funding source, number of centers, and locations**

Trial attribute	CKD N=308	ESRD/CKD on dialysis N=299	Renal transplant N=194	Glomerular disease N=86	Neoplastic N=12	AKI N=84	Metabolic/electrolyte disorders N=3	Nephrolithiasis N=14	Pyelonephritis N=7	Care delivery models N=5	Other <sup>a</sup> N=56
Funding <sup>b</sup>	n=308	n=299	n=194	n=86	n=12	n=84	n=3	n=14	n=7	n=5	n=56
Industry	153 (49.7)	145 (48.5)	94 (48.5)	27 (31.4)	3 (25.0)	17 (20.2)	1 (33.3)	7 (50.0)	3 (42.9)	0 (0.0)	25 (44.6)
NIH	10 (3.2)	12 (4.0)	6 (3.1)	4 (4.7)	0 (0.0)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)	1 (1.8)
Other	145 (47.1)	142 (47.5)	94 (48.5)	55 (64.0)	9 (75.0)	66 (78.6)	2 (66.7)	7 (50.0)	4 (57.1)	4 (80.0)	30 (53.6)
One sponsor or collaborator	210 (68.2)	214 (71.6)	112 (57.7)	57 (66.3)	11 (91.7)	58 (69.0)	1 (33.3)	11 (78.6)	5 (71.4)	1 (20.0)	40 (71.4)
Sponsor & number of centers classification	n=287	n=280	n=187	n=81	n=12	n=79	n=3	n=14	n=7	n=5	n=53
Industry funded - Single center	60 (20.9)	54 (19.3)	41 (21.9)	10 (12.3)	1 (8.3)	9 (11.4)	0 (0.0)	2 (14.3)	1 (14.3)	0 (0.0)	14 (26.4)
Industry funded - Multi-center	81 (28.2)	81 (28.9)	49 (26.2)	16 (19.8)	2 (16.7)	7 (8.9)	1 (33.3)	5 (35.7)	2 (28.6)	0 (0.0)	8 (15.1)
NIH funded - Single center	7 (2.4)	5 (1.8)	3 (1.6)	1 (1.2)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)	1 (1.9)
NIH funded - Multi-center	2 (0.7)	6 (2.1)	3 (1.6)	3 (3.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other - Single center	122 (42.5)	108 (38.6)	79 (42.2)	40 (49.4)	7 (58.3)	53 (67.1)	2 (66.7)	5 (35.7)	3 (42.9)	4 (80.0)	26 (49.1)
Other - Multi-center	15 (5.2)	26 (9.3)	12 (6.4)	11 (13.6)	2 (16.7)	9 (11.4)	0 (0.0)	2 (14.3)	1 (14.3)	0 (0.0)	4 (7.5)
Location	n=287	n=280	n=187	n=81	n=12	n=79	n=3	n=14	n=7	n=5	n=53
US only	127 (44.3)	90 (32.1)	85 (45.5)	18 (22.2)	5 (41.7)	24 (30.4)	1 (33.3)	8 (57.1)	2 (28.6)	3 (60.0)	19 (35.8)
Foreign only	145 (50.5)	174 (62.1)	94 (50.3)	52 (64.2)	7 (58.3)	55 (69.6)	1 (33.3)	5 (35.7)	4 (57.1)	2 (40.0)	32 (60.4)
Both US and Foreign	15 (5.2)	16 (5.7)	8 (4.3)	11 (13.6)	0 (0.0)	0 (0.0)	1 (33.3)	1 (7.1)	1 (14.3)	0 (0.0)	2 (3.8)

Unless otherwise noted, values are n (%). Columns are not mutually exclusive; a study may be counted in more than one column.

<sup>a</sup>Other includes drug studies, pharmacokinetic studies, and studies with other interventions with renal endpoints.

<sup>b</sup>Derived from lead sponsor and collaborator fields.

Abbreviations: AKI, acute kidney infection; CKD, chronic kidney disease; ESRD, end-stage renal disease; NIH, National Institutes of Health; US, United States.